| abstract |
IT REFERS TO BICYCLE COMPOUNDS OF FORMULA (I) WHERE Ar IS PHENYL, NAPHTHYL, QUINOLYL, PYRIDYL OR THIAZOLYL, OPTIONALLY SUBSTITUTED WITH PHENYL, CN, NO2, AMONG OTHER SUBSTITUENTS; X IS O, S, S (O), S (O) 2, AMONG OTHERS; AND IS O, S, S (O), C (= O), AMONG OTHERS; Z IS C (= O) OR12, C (= O) NR13R14 OR 5-TETRAZOLYL, WHERE R12 IS H OR (C1-C7) ALKYL OPTIONALLY SUBSTITUTED WITH HALOGEN; R13 AND R14 ARE EACH H, ALKYL (C1-C5), C (= O) ALKYL (C1-C5) OR S (O) 2ALKYL (C1-C5) OPTIONALLY REPLACED WITH HALOGEN; R1, R2 AND R3 ARE EACH H, HALOGEN, ALKYL (C1-C3) OR O-ALKYL (C1-C3) OPTIONALLY SUBSTITUTED WITH HALOGEN; R4 IS HALOGEN, CN, NO2, OH, C (= O) OH, AMONG OTHERS; p IS FROM 0 TO 3. THE PREFERRED COMPOUNDS ARE: 4 - [(4-CYANE-1-NAPHTHYL) OXY] -1a, 6b-DIHYDRO-1H-CYCLOPROPA [b] [1] BENZOFURAN-1-EXO-CARBOXYL ACID, (1R, 1aR, 6bS) -4- [2- (DIFLUOROMETOXI) -4- (TRIFLUOROMETHYL) PHENOXY] -N- (METHYLSULFONYL) -1a, 6b-DIHYDRO-1H-CYCLOPROPA [b] [1] BENZOFURAN-1- CARBOXAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE AGONISTS OF THE RECEPTOR 40 COUPLED TO PROTEIN G (GPR40), BEING USEFUL IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS |